A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Oral HRS5091 in Healthy Subjects and Chronic Hepatitis B Patients

A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics of Oral HRS5091 in Healthy Subjects With Single or Multiple Dose and Chronic Hepatitis B Patients With Multiple Dose, and Food Effects of HRS5091 in Healthy Subjects

The study is a randomized, Double-Blind, Placebo-Controlled study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and food effect of HRS5091. The study will be conducted in three parts sequentially:

Part 1a will consist of 58 healthy subjects, 5 groups. The purpose of this part is to explore the safety, tolerability and pharmacokinetics of single doses of HRS5091 tablet in healthy subjects.

Part 1b will consist of 18 healthy subjects and it is one of groups in Part 1a.The purpose of this part is to explore food effect of HRS5091 in healthy subjects.

Part 1c will consist of 10 healthy subjects, 1 groups. The purpose of this part is to explore the safety, tolerability and pharmacokinetics of multiple doses of HRS5091 tablet in healthy subjects.

Part 2 will consist of 30 CHB patients.The purpose of this part is to explore the safety, tolerability and pharmacokinetics, pharmacodynamics of multiple doses of HRS5091 tablet in naïve and treatment-discontinued chronic hepatitis B (CHB) patients.

Study Overview

• Status: Active, not recruiting
• Conditions: Chronic Hepatitis B
• Intervention / Treatment: Drug: HRS5091

• Study Type: Interventional
• Enrollment (Actual): 108
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 200433
      • Shanghai Changhai Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: ADULT; OLDER_ADULT; CHILD
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy subjects

  1. Signed informed consent.
  2. Aged 18~55.
  3. Body weight ≥ 50 kg for male; ≥ 45 kg for female, body mass index (BMI) between 18 to 28 kg/m².
  4. Vital signs, physical examination, laboratory results are within normal range or considered not clinically significant.
  5. Female subjects (including partner) of childbearing potential must be using a medically acceptable form of birth control.

• CHB subjects

  1. Signed informed consent.
  2. Aged 18~65.

  3. CHB subjects should meet one of the following two criteria:

     • IgM(immunoglobulin M) HBcAb negative and HBsAg positive.
     • Two recorded HBsAg positive, and the time interval between the two tests was at least 6 months, one of which was the result of this screening

  4. CHB subjects should also meet the following criteria:

     • No treatment with nucleosides analogues or discontinued treatment with nucleosides analogues least 6 months at screening
     • Have not received interferon therapy or discontinued treatment with interferon analogues least 3 months at screening
     • HBeAg positive，HBV(hepatitis B virus) DNA≥ 20000 IU/mL; HBeAg negative, HBV DNA≥ 2000 IU/mL
     • ALT(Alanine aminotransferase)> 1 ULN(upper limit of normal) by two measurements within 6 months before enrollment.The interval between two measurements shall exceed 14 days;
  5. Female subjects (including partner) of childbearing potential must be using a medically acceptable form of birth control.

Exclusion Criteria:

• Healthy subjects

  1. Currently suffering from cardiovascular, liver, kidney, digestive, nervous, blood, thyroid or mental diseases.
  2. Have a digestive system disease or a medical history of severe digestive system disease at present or in the past month.
  3. Have severe infection, severe trauma or major surgical operations within 3 months. Plan to receive surgery during the trial and within two weeks after the end of the trial.
  4. 12-ECG test have clinical significant abnormality or the QT interval (QTc) > 470 ms(male)/QTc)> 480 ms(male) or<300ms(female).
  5. Have a medical history of immune-mediated diseases.
  6. Screening for infectious diseases is positive,Including HBsAg, Anti-HCV(hepatitis C virus), TPPA(Treponema pallidum particle agglutination assay), Anti-HIV.Treponema pallidum antibody screen positive, at the investigator's discretion in conjunction with RPR(rapid plasma reagin assay) results.
  7. Suspected allergy to any ingredient in the study drug.
  8. Have any drug that inhibits or induces liver metabolism within 1 month.
  9. Take any prescription drugs, over-the-counter drugs and Chinese herbal medicines within 14 days before taking the study drug, or plan to take other drugs during the test period.
  10. Participated in clinical trials of any drug or medical device within 3 months before screening.
  11. Had donated blood/blood transfusion≥ 200 mL within 1 months prior to screening or donated blood or blood transfusion≥ 450 mL within 3 months prior to screening.
  12. The average daily smoking ≥ 5 cigarettes within three months; the average daily alcohol intake in a month exceeds 15 g (15 g alcohol is equivalent to 450 mL beer or 150 mL wine or 50 mL low-alcohol);
  13. Keep smoking, drinking alcohol or consuming caffeinated foods or beverages (more than 8 cups, 1 cup = 250 mL) 2 days before taking the study drug and during the study; and those who have special dietary requirements and cannot follow the unified diet;
  14. Pregnant or lactating women;
  15. Drug screening or alcohol breath test is positive.
  16. Other conditions that the investigator believes the subject is not suitable.

• CHB subjects

  1. Currently suffering from serious cardiovascular, liver, kidney, digestive, nervous, blood, thyroid or mental diseases other than hepatitis B.
  2. People have acute or chronic liver disease by non-HBV infection (Whether fatty liver is excluded or not is determined by the investigator).
  3. Liver stiffness (LSM)> 12.4 kPa(kilopascal) by noninvasive transient liver elastography (eg Fibroscan®) or recorded liver biopsy suggesting cirrhosis or extensive fibrosis within 6 months before randomization.
  4. Primary liver cancer, high-risk groups of primary liver cancer or AFP(alpha fetoprotein)> 50g/L;
  5. Have clinically demonstrated or history of liver function decompensation, including but not limited to: hepatic encephalopathy, hepatorenal syndrome, splenomegaly, ascites, etc.;

  6. Laboratory inspection:

     1. Platelet count <90×10⁹/L;
     2. White blood cell count <3.0×10⁹/L;
     3. Absolute value of neutrophils <1.5×10⁹/L;
     4. Serum total bilirubin>2×ULN;
     5. Albumin <30 g/L;
     6. Creatinine clearance rate ≤60ml/min;
     7. INR(international normalized ratio)>1.5;
     8. ALT> 5 ULN on screening/baseline visit
  7. HIV and/or syphilis antibody positive (Treponema pallidum antibody screen positive, at the investigator's discretion in conjunction with RPR results).
  8. Subjects who have previously received organ/bone marrow transplantation;
  9. Have used immunosuppressants, immunomodulators or cytotoxic drugs within 6 months before the study medication;
  10. Suspected allergy to any ingredient in the study drug.
  11. 12-ECG test have clinical significant abnormality or the QT interval (QTc) > 470 ms(male)/QTc)> 480 ms(male) or<300ms(female).
  12. The average daily smoking ≥ 5 cigarettes within three months; the average daily alcohol intake in a month exceeds 15 g (15 g alcohol is equivalent to 450 mL beer or 150 mL wine or 50 mL low-alcohol);
  13. Keep smoking, drinking alcohol or consuming caffeinated foods or beverages (more than 8 cups, 1 cup = 250 mL) 2 days before taking the study drug and during the study; and those who have special dietary requirements and cannot follow the unified diet;
  14. Pregnant or lactating women;
  15. Drug screening or alcohol breath test is positive.
  16. Other conditions that the investigator believes the subject is not suitable.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: OTHER
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: TRIPLE

Number of Arms

10

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Part 1a Treatment group 1; Intervention: Drug1: HRS5091, dose 1; Drug2: Placebo Healthy subjects	Drug: HRS5091; Single dose in group 1-5 Multiple doses in group 6-9; Other Names: Placebo
EXPERIMENTAL: Part 1a Treatment group 2; Intervention: Drug1: HRS5091, dose 2; Drug2: Placebo Healthy subjects	Drug: HRS5091; Single dose in group 1-5 Multiple doses in group 6-9; Other Names: Placebo
EXPERIMENTAL: Part 1a Treatment group 3; Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo Healthy subjects	Drug: HRS5091; Single dose in group 1-5 Multiple doses in group 6-9; Other Names: Placebo
EXPERIMENTAL: Part 1a Treatment group 4; Intervention: Drug1: HRS5091, dose 4; Drug2: Placebo Healthy subjects	Drug: HRS5091; Single dose in group 1-5 Multiple doses in group 6-9; Other Names: Placebo
EXPERIMENTAL: Part 1a Treatment group 5; Intervention: Drug1: HRS5091, dose 5; Drug2: Placebo Healthy subjects	Drug: HRS5091; Single dose in group 1-5 Multiple doses in group 6-9; Other Names: Placebo
EXPERIMENTAL: Part 1b Treatment group 3; Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo Healthy subjects Food effect	Drug: HRS5091; Single dose in group 1-5 Multiple doses in group 6-9; Other Names: Placebo
EXPERIMENTAL: Part 1c Treatment group 6; Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo Healthy subjects	Drug: HRS5091; Single dose in group 1-5 Multiple doses in group 6-9; Other Names: Placebo
EXPERIMENTAL: Part 2 Treatment group 7; Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo CHB subjects	Drug: HRS5091; Single dose in group 1-5 Multiple doses in group 6-9; Other Names: Placebo
EXPERIMENTAL: Part 2 Treatment group 8; Intervention: Drug1: HRS5091, dose 4; Drug2: Placebo CHB subjects	Drug: HRS5091; Single dose in group 1-5 Multiple doses in group 6-9; Other Names: Placebo
EXPERIMENTAL: Part 2 Treatment group 9; Intervention: Drug1: HRS5091, dose 5; Drug2: Placebo CHB subjects	Drug: HRS5091; Single dose in group 1-5 Multiple doses in group 6-9; Other Names: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The incidence and severity of treatment-related	adverse events as assessed by CTCAE v5.0	29 DAYS for Group 1.2.4.5; 58 DAYS for Group 3; 42 DAYS for Group 6；56 DAYS for Group 7-9；
Maximum Plasma Concentration [Cmax]	Pharmacokinetic parameters of HRS5091, main metabolite and identified major metabolites in plasma	0-672 hours after each dose for Group 1-9
Area under the concentration time curve [AUC]	Pharmacokinetic parameters of HRS5091, main metabolite and identified major metabolites in plasma	0-672 hours after each dose for Group 1-9
Time to maximum plasma concentration [Tmax]	Pharmacokinetic parameters of HRS5091, main metabolite and identified major metabolites in plasma	0-672 hours after each dose for Group 1-9
Apparent clearance [CL/F]	Pharmacokinetic parameters of HRS5091, main metabolite and identified major metabolites in plasma	0-672 hours after each dose for Group 1-9
Half-time [t1/2]	Pharmacokinetic parameters of HRS5091, main metabolite and identified major metabolites in plasma	0-672 hours after each dose for Group 1-9
Apparent volume of distribution [Vz/F(Vd)]	Pharmacokinetic parameters of HRS5091, main metabolite and identified major metabolites in plasma	0-672 hours after each dose for Group 1-9
Mean retention time [MRT]	Pharmacokinetic parameters of HRS5091, main metabolite and identified major metabolites in plasma	0-672 hours after each dose for Group 1-9

Collaborators and Investigators

• Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Study record dates

Study Major Dates

• Study Start (ACTUAL): July 28, 2020
• Primary Completion (ANTICIPATED): November 23, 2021
• Study Completion (ANTICIPATED): November 23, 2021

Study Registration Dates

• First Submitted: July 13, 2020
• First Submitted That Met QC Criteria: July 17, 2020
• First Posted (ACTUAL): July 21, 2020

Study Record Updates

• Last Update Posted (ACTUAL): October 22, 2021
• Last Update Submitted That Met QC Criteria: October 19, 2021
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Hepatitis, Viral, Human; Hepadnaviridae Infections; DNA Virus Infections; Enterovirus Infections; Picornaviridae Infections; Hepatitis B; Hepatitis; Hepatitis A; Hepatitis B, Chronic; Hepatitis, Chronic
• Other Study ID Numbers: HRS5091-101

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No